Scientific Research Center, Institute of Oncology, Vilnius University, Vilnius, Lithuania.
Adv Med Sci. 2011;56(2):285-90. doi: 10.2478/v10039-011-0047-6.
The purpose of this study was to evaluate the overall survival of patients with triple negative breast cancer and the impact of different adjuvant chemotherapy regimens on survival.
MATERIAL/METHODS: The study group consisted of 99 breast cancer patients with immunohistochemically confirmed triple negative breast cancer. The impact of various factors as well as the impact of different chemotherapy regimens on survival was evaluated.
The overall survival of breast cancer patients was 97.0% (95% CI 90.9-99.0), 84.9% (95% CI 76.1-90.6) and 66.5% (95% CI 55.5-75.3) 10, 30 and 60 months after diagnosis, respectively. Univariate analysis demonstrated that the following were significant risk factors for breast cancer patients survival: patient's age, stage of disease, tumour size, lymph node status, type of surgery and chemotherapy. Better survival was related to younger patients' age, smaller tumour size, lower stage of disease, no lymph nodes involvement. Survival rates were higher among patients who received adjuvant chemotherapy and underwent quadrantectomy. In the multivariate statistical analysis the significant independent prognostic variables influencing survival were lymph node status and adjuvant chemotherapy. Survival rates of the patients, who received adjuvant anthracycline containing chemotherapy were higher, than those in non-anthracycline containing treatment group, but the difference was not statistically significant.
Patients who had lymph node status N2-3 and those who did not receive adjuvant chemotherapy showed worse prognosis and survival than other patients. The impact of chemotherapy type (anthracycline containing or non-anthracycline containing) on patients survival was not statistically significant.
本研究旨在评估三阴性乳腺癌患者的总生存率以及不同辅助化疗方案对生存率的影响。
材料/方法：研究组纳入了 99 例经免疫组化证实的三阴性乳腺癌患者。评估了各种因素以及不同化疗方案对生存率的影响。
乳腺癌患者的总生存率分别为诊断后 10、30 和 60 个月时的 97.0%（95%CI 90.9-99.0）、84.9%（95%CI 76.1-90.6）和 66.5%（95%CI 55.5-75.3）。单因素分析显示，以下因素是乳腺癌患者生存的显著危险因素：患者年龄、疾病分期、肿瘤大小、淋巴结状态、手术类型和化疗。更好的生存与更年轻的患者年龄、更小的肿瘤大小、更低的疾病分期、无淋巴结受累有关。接受辅助化疗和象限切除术的患者生存率更高。多因素统计分析显示，影响生存的独立预后因素为淋巴结状态和辅助化疗。接受含蒽环类药物辅助化疗的患者生存率更高，但与非蒽环类药物治疗组相比，差异无统计学意义。
淋巴结状态为 N2-3 且未接受辅助化疗的患者预后和生存率较其他患者差。化疗类型（含蒽环类或非蒽环类）对患者生存的影响无统计学意义。
